Académique Documents
Professionnel Documents
Culture Documents
CM
MY
CY
CMY
23/02/15
11:11
INDEX_.pdf
CM
MY
CY
CMY
23/02/15
11:02
INDEX india_.pdf
10/07/15
17:25
CM
A. Pizzoccaro
MY
CY
CMY
A. Perra
13
T. Lotti
33
BIANCA.pdf
CM
MY
CY
CMY
09/02/15
17:36
1A-Presentazione-manifesto India.pdf
10/07/15
17:28
GUNA S.p.a.
Advanced Therapies
Company Introduction
Dear Doctors,
CM
MY
CY
CMY
Alessandro Pizzoccaro
President and Founder of Guna S.p.a.
BIANCA.pdf
CM
MY
CY
CMY
09/02/15
17:36
1A-Presentazione-manifesto India.pdf
10/07/15
17:28
The Manifesto
Vision-Mission-Values
A Pharmaceutical
Company
C
CM
MY
CY
CMY
Guided by
ethical principles
Devoted to
scientific research
Focused on
education and scientific information
addressed to doctors and pharmacists
Aimed at promoting
biological medicinal products:
-unique -effective -innovative -without side effects
Targeted at affirming the values and the model of
Human Centered Medicine
in harmony with Nature
Contributing to make the World a
better place to live
1B-Azienda farmaceutica.pdf
CM
MY
CY
CMY
23/02/15
11:03
1B-Azienda farmaceutica.pdf
CM
MY
CY
CMY
23/02/15
11:03
1B-Azienda farmaceutica.pdf
CM
MY
CY
CMY
23/02/15
11:03
CM
MY
CY
CMY
23/02/15
11:02
CM
MY
CY
CMY
23/02/15
11:02
CM
MY
CY
CMY
23/02/15
11:02
CM
MY
CY
CMY
23/02/15
11:02
CM
MY
CY
CMY
23/02/15
11:02
BIANCA.pdf
CM
MY
CY
CMY
09/02/15
17:36
2A-PERRA.pdf
CM
MY
CY
CMY
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
17/09/15
09:59
2A-PERRA.pdf
CM
MY
CY
CMY
10
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
11
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
12
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
13
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
14
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
15
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
16
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
17
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
18
16/09/15
17:11
2A-PERRA.pdf
CM
MY
CY
CMY
19
16/09/15
17:11
BIANCA.pdf
CM
MY
CY
CMY
09/02/15
17:36
3-LOTTI.pdf
10/07/15
17:22
33
CM
MY
CY
CMY
Torello Lotti
Professor & Chair of Dermatology and Venereology;
Director of the Center for Interdisciplinary Studies of Regenerative Sciences. University of Rome
Guglielmo Marconi Rome, Italy; Director Institute of Dermatology LifeCronos, Florence, Italy;
President World Health Academy Foundation, Zurich, Switzerland.
ENDOCRINE SYSTEM
IMMUNE SYSTEM
3-LOTTI.pdf
10/07/15
17:22
34
CM
MY
CY
CMY
3-LOTTI.pdf
10/07/15
17:22
CM
MY
CY
CMY
35
3-LOTTI.pdf
10/07/15
17:22
36
CM
MY
CY
CMY
The therapy cycles can be repeated according to the clinical history of every single patient,
the severity of the disease and the individual response of each patient. All the medicines can
also be administered all together, dissolved in a little water, keeping them at least for 30
seconds in the mouth, preferably far from meals.
3-LOTTI.pdf
10/07/15
17:22
37
CM
MY
CY
CMY
Cytokines UP
TNF-
IFN-
IL-1
IL-2
IL-6
IL-8
IL-17
Th2
VITILIGO
HEALTH
VITILIGO
Th1/Th17
Cytokines DOWN
TGF-
IL-4
3-LOTTI.pdf
10/07/15
17:22
38
CM
MY
CY
CMY
Keratinocytes-melanocytes
crosstalk: the role of
basic-Fibroblast Growth Factor
Keratinocytes are the major source of cytokines at the epidermal level with proliferative,
immunological and inflammatory properties.
The sophisticated mechanism of cross-talk
between keratinocytes and melanocytes is
essential for proper skin pigmentation; the
numerical ratio between keratinocytes and
melanocytes is 10 to 1 and the first ones
produce a set of signaling molecules essential
for the maintenance and functionality of the
second ones.
The cytokine network between keratinocytes
and melanocytes includes:
SCF (stem cells factor)
ETs (endothelins)
b-FGF (basic-fibroblast growth factor)
These keratinocytes-derived cytokines are
fundamental for melanocytes growth,
differentiation and migration; in particular,
b-FGF exerts a paracrine signaling function
between keratinocytes and melanocytes [29].
b-FGF is not only a mitotic and migrating
factor but it is also involved in radical oxygen
substances detoxifying processes by inhibiting
ROS (and related damages) via activation of
PI3K/Akt and consequent inhibition of
NF-kB nuclear translocation [30] (Figure 3).
3-LOTTI.pdf
10/07/15
17:22
39
KERATINOCYTE
NF-kB-IkB
IkB-P-P
NF-kB
NO
LA
ME
YTE
MELANIN
APOPTOSIS
CM
MY
CY
CMY
3-LOTTI.pdf
10/07/15
17:22
40
CM
MY
CY
CMY
3-LOTTI.pdf
10/07/15
17:22
CM
MY
CY
CMY
KERATINOCYTES
PARACRINE HYPOTHESIS
KERATINOCYTES
APOPTOSIS
41
NF-kB
PI3K/PKb
TNF-
MELANOCYTES
GROWTH
VITILIGO
Figure 4 Keratinocytes/Melanocytes interplay
and inflammation in Vitiligo onset
3-LOTTI.pdf
10
10/07/15
17:22
42
Vitiligo
CM
MY
CY
Conclusions
CMY
3-LOTTI.pdf
11
10/07/15
17:22
43
References
CM
MY
CY
CMY
1. Ader R, Cohen N.
Psychoneuroimmunology: conditioning and stress.
Annu Rev Psychol 1993;44: 53-85.
2. Ader R, Cohen N, Felten D.
Psychoneuroimmunology: interactions between the nervous
system and the immune system.
Lancet 1995;345(8942): 99-103.
3. Brazzini B, Ghersetich I, Hercogova J, Lotti T.
The neuro-immuno-cutaneous-endocrine network: relationship between mind and skin.
Dermatol Ther 2003;16(2): 123-31.
4. Lotti T, Bianchi B, Ghersetich I, Brazzini B,
Hercogova J.
Can the brain inhibit inflammation generated in the skin?
The lesson of gamma-melanocyte-stimulating hormone.
Int J Dermatol 2002;41(6): 311-8.
5. Ngoc PL, Gold DR, Tzianabos AO, Weiss ST,
Celedn JC.
Cytokines, allergy, and asthma.
Curr Opin Allergy Clin Immunol 2005;5(2):
161-6.
6. Loureno EV, La Cava A.
Cytokines in systemic lupus erythematosus.
Curr Mol Med 2009;9(3): 242-54.
7. Skurkovich S, Korotky NG, Sharova NM,
Skurkovich B.
Treatment of alopecia areata with anti-interferon-gamma
antibodies.
J Investig Dermatol Symp Proc 2005;10(3): 283-4.
8. Numerof RP, Asadullah K.
Cytokine and anti-cytokine therapies for psoriasis and
atopic dermatitis. BioDrugs; 2006;20: 93-103.
9. Wallis RS.
Reactivation of latent tuberculosis by TNF blockade: the
role of interferon gamma.
J Investig Dermatol Symp Proc 2007;12(1): 16-21.
10. Guerra I, Algaba A, Prez-Calle JL, Chaparro M,
Marn-Jimnez I, et al (2012).
Induction of psoriasis with anti-TNF agents in patients
with inflammatory bowel disease: a report of 21 cases.
Crohns Colitis;6(5):518-23.
11. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ,
Jacobs DR Jr, et al. (2012)
Hormones and endocrine-disrupting chemicals: low-dose
effects and nonmonotonic dose responses. Endocr Rev
33(3): 378-455.
12. Biancotto A, Wank A, Perl S, Cook W, Olnes MJ, et
al. (2013)
Baseline levels and temporal stability of 27 multiplexed
serum cytokine concentrations in healthy subjects.
PLoS One 8(12):e76091.
3-LOTTI.pdf
12
10/07/15
17:22
44
CM
MY
CY
CMY
3-LOTTI.pdf
CM
MY
CY
CMY
13
10/07/15
17:22
BIANCA.pdf
CM
MY
CY
CMY
09/02/15
17:36
BIANCA.pdf
CM
MY
CY
CMY
09/02/15
17:36
COPERTINA.pdf
CM
CM
MY
MY
CY
CY
CMY
CMY
17/09/15
09:00
23/02/15
11:11
7EX039 B
4 di copertina.pdf